ACAD · Acadia Pharmaceuticals Inc
United States · RS rating 14 · As of 2026-10-14
| Price | 19.25 USD |
|---|---|
| 1-day change | +3.4% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 7 / 15 / 38 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 36 / 10 / 52 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +280.9% |
| Sales growth Q/Q | +1.9% |
| Distance from 52-week high | +37.0% |
| Market cap (USD) | $3.8B |